JP2008518608A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008518608A5 JP2008518608A5 JP2007539463A JP2007539463A JP2008518608A5 JP 2008518608 A5 JP2008518608 A5 JP 2008518608A5 JP 2007539463 A JP2007539463 A JP 2007539463A JP 2007539463 A JP2007539463 A JP 2007539463A JP 2008518608 A5 JP2008518608 A5 JP 2008518608A5
- Authority
- JP
- Japan
- Prior art keywords
- lna oligonucleotide
- lna
- composition
- conjugate
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108091034117 Oligonucleotide Proteins 0.000 claims 32
- 239000000203 mixture Substances 0.000 claims 19
- 239000008194 pharmaceutical composition Substances 0.000 claims 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 10
- 201000010099 disease Diseases 0.000 claims 9
- 239000002773 nucleotide Substances 0.000 claims 9
- 125000003729 nucleotide group Chemical group 0.000 claims 9
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 5
- 201000004681 Psoriasis Diseases 0.000 claims 5
- 201000011510 cancer Diseases 0.000 claims 5
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 5
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 4
- 230000033115 angiogenesis Effects 0.000 claims 4
- 230000002491 angiogenic effect Effects 0.000 claims 4
- 208000002780 macular degeneration Diseases 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 201000004624 Dermatitis Diseases 0.000 claims 2
- 206010012434 Dermatitis allergic Diseases 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 2
- 208000034578 Multiple myelomas Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 206010038389 Renal cancer Diseases 0.000 claims 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 2
- 208000000260 Warts Diseases 0.000 claims 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 201000008937 atopic dermatitis Diseases 0.000 claims 2
- 208000010668 atopic eczema Diseases 0.000 claims 2
- 201000010881 cervical cancer Diseases 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 201000010982 kidney cancer Diseases 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 201000010153 skin papilloma Diseases 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical group OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 230000006907 apoptotic process Effects 0.000 claims 1
- 239000008365 aqueous carrier Substances 0.000 claims 1
- 230000010261 cell growth Effects 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 150000002500 ions Chemical class 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 108091033319 polynucleotide Proteins 0.000 claims 1
- 239000002157 polynucleotide Substances 0.000 claims 1
- 102000040430 polynucleotide Human genes 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US62656304P | 2004-11-09 | 2004-11-09 | |
| US60/626,563 | 2004-11-09 | ||
| US64718605P | 2005-01-25 | 2005-01-25 | |
| US60/647,186 | 2005-01-25 | ||
| US69972105P | 2005-07-15 | 2005-07-15 | |
| US60/699,721 | 2005-07-15 | ||
| US72462105P | 2005-10-07 | 2005-10-07 | |
| US60/724,621 | 2005-10-07 | ||
| PCT/DK2005/000721 WO2006050734A2 (en) | 2004-11-09 | 2005-11-09 | Potent lna oligonucleotides for the inhibition of hif-1a expression |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011177731A Division JP2011229540A (ja) | 2004-11-09 | 2011-08-15 | ＨＩＦ−１ａ発現阻害のための強力なＬＮＡオリゴヌクレオチド |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008518608A JP2008518608A (ja) | 2008-06-05 |
| JP2008518608A5 true JP2008518608A5 (https=) | 2008-11-27 |
| JP4825807B2 JP4825807B2 (ja) | 2011-11-30 |
Family
ID=36177326
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007539463A Expired - Fee Related JP4825807B2 (ja) | 2004-11-09 | 2005-11-09 | ＨＩＦ−１ａ発現阻害のための強力なＬＮＡオリゴヌクレオチド |
| JP2011177731A Withdrawn JP2011229540A (ja) | 2004-11-09 | 2011-08-15 | ＨＩＦ−１ａ発現阻害のための強力なＬＮＡオリゴヌクレオチド |
| JP2014031436A Withdrawn JP2014098027A (ja) | 2004-11-09 | 2014-02-21 | ＨＩＦ−１ａ発現阻害のための強力なＬＮＡオリゴヌクレオチド |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011177731A Withdrawn JP2011229540A (ja) | 2004-11-09 | 2011-08-15 | ＨＩＦ−１ａ発現阻害のための強力なＬＮＡオリゴヌクレオチド |
| JP2014031436A Withdrawn JP2014098027A (ja) | 2004-11-09 | 2014-02-21 | ＨＩＦ−１ａ発現阻害のための強力なＬＮＡオリゴヌクレオチド |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US7589190B2 (https=) |
| EP (1) | EP1833840B9 (https=) |
| JP (3) | JP4825807B2 (https=) |
| KR (1) | KR101176245B1 (https=) |
| AT (1) | ATE476441T1 (https=) |
| AU (1) | AU2005304112B2 (https=) |
| BR (1) | BRPI0515726A8 (https=) |
| CA (1) | CA2587173C (https=) |
| DE (1) | DE602005022768D1 (https=) |
| DK (1) | DK1833840T3 (https=) |
| EA (1) | EA014097B1 (https=) |
| IL (1) | IL183054A0 (https=) |
| MX (1) | MX2007005558A (https=) |
| NO (1) | NO341878B1 (https=) |
| NZ (1) | NZ555644A (https=) |
| WO (1) | WO2006050734A2 (https=) |
Families Citing this family (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004046160A2 (en) | 2002-11-18 | 2004-06-03 | Santaris Pharma A/S | Amino-lna, thio-lna and alpha-l-oxy-ln |
| US7144999B2 (en) * | 2002-11-23 | 2006-12-05 | Isis Pharmaceuticals, Inc. | Modulation of hypoxia-inducible factor 1 alpha expression |
| ATE443765T1 (de) * | 2003-03-21 | 2009-10-15 | Santaris Pharma As | Analoga kurzer interferierender rna (sirna) |
| WO2005073378A1 (en) * | 2004-01-30 | 2005-08-11 | Santaris Pharma A/S | MODIFIED SHORT INTERFERING RNA (MODIFIED siRNA) |
| US9447138B2 (en) | 2004-11-09 | 2016-09-20 | Roche Innovation Center Copenhagen A/S | Potent LNA oligonucleotides for the inhibition of HIF-1a expression |
| MX2007005558A (es) * | 2004-11-09 | 2008-01-31 | Santaris Pharma As | Oligonucleotidos de lna potentes para la inhibicion dela expresion de hif-1a. |
| JP5713377B2 (ja) | 2005-12-28 | 2015-05-07 | ザ スクリプス リサーチ インスティテュート | 薬物標的としての天然アンチセンスおよび非コードｒｎａ転写物 |
| WO2007085485A2 (en) * | 2006-01-27 | 2007-08-02 | Santaris Pharma A/S | Lna modified phosphorothiolated oligonucleotides |
| WO2007107162A2 (en) * | 2006-03-23 | 2007-09-27 | Santaris Pharma A/S | Small internally segmented interfering rna |
| JP2009536222A (ja) | 2006-05-05 | 2009-10-08 | アイシス ファーマシューティカルズ， インコーポレーテッド | Ｐｃｓｋ９の発現を調節するための化合物および方法 |
| WO2008034123A2 (en) * | 2006-09-15 | 2008-03-20 | Enzon Pharmaceuticals, Inc. | Polymeric conjugates containing positively-charged moieties |
| EP2149605B1 (en) | 2007-03-22 | 2013-07-03 | Santaris Pharma A/S | Short RNA antagonist compounds for the modulation of target mRNA |
| DK2149605T3 (da) * | 2007-03-22 | 2013-09-30 | Santaris Pharma As | Korte RNA antagonist forbindelser til modulering af det ønskede mRNA |
| EP2186528B1 (en) | 2007-08-06 | 2014-03-19 | Senju Pharmaceutical Co., Ltd. | Pharmaceutical containing hif-1 alpha and hif-2 alpha expression inhibitor |
| EP2195428B1 (en) | 2007-09-19 | 2013-12-11 | Applied Biosystems, LLC | SiRNA SEQUENCE-INDEPENDENT MODIFICATION FORMATS FOR REDUCING OFF-TARGET PHENOTYPIC EFFECTS IN RNAi, AND STABILIZED FORMS THEREOF |
| WO2009043759A2 (en) * | 2007-10-04 | 2009-04-09 | Santaris Pharma A/S | Short rna antagonist compounds for the modulation of hif1alpha |
| CN102239260B (zh) | 2008-10-03 | 2017-04-12 | 库尔纳公司 | 通过抑制针对载脂蛋白‑a1的天然反义转录物治疗载脂蛋白‑a1相关疾病 |
| ES2629630T3 (es) | 2008-12-04 | 2017-08-11 | Curna, Inc. | Tratamiento de enfermedades relacionadas con eritropoyetina (EPO) mediante inhibición del transcrito antisentido natural a EPO |
| ES2600781T3 (es) | 2008-12-04 | 2017-02-10 | Curna, Inc. | Tratamiento para enfermedades relacionadas con el factor de crecimiento del endotelio vascular (vegf) mediante la inhibición de transcritos antisentido naturales de vegf |
| US20110294870A1 (en) | 2008-12-04 | 2011-12-01 | Opko Curna, Llc | Treatment of tumor suppressor gene related diseases by inhibition of natural antisense transcript to the gene |
| ES2762610T3 (es) | 2009-02-12 | 2020-05-25 | Curna Inc | Tratamiento de enfermedades relacionadas con el factor neurotrófico derivado de cerebro (BDNF) por inhibición de transcrito antisentido natural para BDNF |
| CN102482677B (zh) | 2009-03-16 | 2017-10-17 | 库尔纳公司 | 通过抑制nrf2的天然反义转录物治疗核因子(红细胞衍生2)‑样2(nrf2)相关疾病 |
| WO2010107740A2 (en) | 2009-03-17 | 2010-09-23 | Curna, Inc. | Treatment of delta-like 1 homolog (dlk1) related diseases by inhibition of natural antisense transcript to dlk1 |
| CN103223177B (zh) | 2009-05-06 | 2016-08-10 | 库尔纳公司 | 通过针对脂质转运和代谢基因的天然反义转录物的抑制治疗脂质转运和代谢基因相关疾病 |
| ES2609655T3 (es) | 2009-05-06 | 2017-04-21 | Curna, Inc. | Tratamiento de enfermedades relacionadas con tristetraprolina (TTP) mediante inhibición de transcrito antisentido natural para TTP |
| JP5931720B2 (ja) | 2009-05-08 | 2016-06-08 | クルナ・インコーポレーテッド | Ｄｍｄファミリーに対する天然アンチセンス転写物の抑制によるジストロフィンファミリー関連疾患の治療 |
| DK2432881T3 (en) | 2009-05-18 | 2018-02-26 | Curna Inc | TREATMENT OF REPROGRAMMING FACTOR-RELATED DISEASES BY INHIBITING NATURAL ANTISENSE TRANSCRIPTS TO A REPROGRAMMING FACTOR |
| CA2762987A1 (en) | 2009-05-22 | 2010-11-25 | Joseph Collard | Treatment of transcription factor e3 (tfe3) and insulin receptor substrate 2 (irs2) related diseases by inhibition of natural antisense transcript to tfe3 |
| KR101704988B1 (ko) | 2009-05-28 | 2017-02-08 | 큐알엔에이, 인크. | 항바이러스 유전자에 대한 천연 안티센스 전사체의 억제에 의한 항바이러스 유전자 관련된 질환의 치료 |
| US8951981B2 (en) | 2009-06-16 | 2015-02-10 | Curna, Inc. | Treatment of paraoxonase 1 (PON1) related diseases by inhibition of natural antisense transcript to PON1 |
| WO2010148050A2 (en) | 2009-06-16 | 2010-12-23 | Curna, Inc. | Treatment of collagen gene related diseases by inhibition of natural antisense transcript to a collagen gene |
| WO2010151671A2 (en) | 2009-06-24 | 2010-12-29 | Curna, Inc. | Treatment of tumor necrosis factor receptor 2 (tnfr2) related diseases by inhibition of natural antisense transcript to tnfr2 |
| EP2446037B1 (en) | 2009-06-26 | 2016-04-20 | CuRNA, Inc. | Treatment of down syndrome gene related diseases by inhibition of natural antisense transcript to a down syndrome gene |
| CN102712925B (zh) | 2009-07-24 | 2017-10-27 | 库尔纳公司 | 通过抑制sirtuin(sirt)的天然反义转录物来治疗sirtuin(sirt)相关性疾病 |
| CN102762731B (zh) | 2009-08-05 | 2018-06-22 | 库尔纳公司 | 通过抑制针对胰岛素基因(ins)的天然反义转录物来治疗胰岛素基因(ins)相关的疾病 |
| CN104313027B (zh) | 2009-08-11 | 2018-11-20 | 库尔纳公司 | 通过抑制脂连蛋白(adipoq)的天然反义转录物治疗脂连蛋白(adipoq)相关疾病 |
| KR101805213B1 (ko) | 2009-08-21 | 2017-12-06 | 큐알엔에이, 인크. | Ｃｈｉｐ에 대한 천연 안티센스 전사체의 억제에 의한 “ｈｓｐ70-상호작용 단백질(ｃｈｉｐ)의 ｃ-말단” 관련된 질환의 치료 |
| CA2771172C (en) | 2009-08-25 | 2021-11-30 | Opko Curna, Llc | Treatment of 'iq motif containing gtpase activating protein' (iqgap) related diseases by inhibition of natural antisense transcript to iqgap |
| US20120295952A1 (en) | 2009-09-25 | 2012-11-22 | Curna, Inc. | Treatment of filaggrin (flg) related diseases by modulation of flg expression and activity |
| AR078770A1 (es) | 2009-10-27 | 2011-11-30 | Elara Pharmaceuticals Gmbh | Derivados de dihidrobenzo oxacinas y tiazinas, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades inflamatorias e hiperproliferativas. |
| JP6025567B2 (ja) | 2009-12-16 | 2016-11-16 | カッパーアールエヌエー，インコーポレイテッド | 膜結合転写因子ペプチダーゼ、部位１（ｍｂｔｐｓ１）に対する天然アンチセンス転写物の阻害によるｍｂｔｐｓ１関連性疾患の治療 |
| RU2619185C2 (ru) | 2009-12-23 | 2017-05-12 | Курна, Инк. | Лечение заболеваний, связанных с разобщающим белком 2 (ucp2), путем ингибирования природного антисмыслового транскрипта к ucp2 |
| CN102869776B (zh) | 2009-12-23 | 2017-06-23 | 库尔纳公司 | 通过抑制肝细胞生长因子(hgf)的天然反义转录物而治疗hgf相关疾病 |
| EP2519633B1 (en) | 2009-12-29 | 2017-10-25 | CuRNA, Inc. | Treatment of nuclear respiratory factor 1 (nrf1) related diseases by inhibition of natural antisense transcript to nrf1 |
| ES2585829T3 (es) | 2009-12-29 | 2016-10-10 | Curna, Inc. | Tratamiento de las enfermedades relacionadas con la proteína tumoral 63 (p63) por inhibición de transcripción antisentido natural a p63 |
| CA2785727C (en) | 2009-12-31 | 2020-01-07 | Curna, Inc. | Treatment of insulin receptor substrate 2 (irs2) related diseases by inhibition of natural antisense transcript to irs2 and transcription factor e3 (tfe3) |
| CA2785832A1 (en) | 2010-01-04 | 2011-07-07 | Curna, Inc. | Treatment of interferon regulatory factor 8 (irf8) related diseases by inhibition of natural antisense transcript to irf8 |
| KR101853509B1 (ko) | 2010-01-06 | 2018-04-30 | 큐알엔에이, 인크. | 췌장 발달 유전자에 대한 천연 안티센스 전사체의 억제에 의한 췌장 발달 유전자와 관련된 질환의 치료 |
| JP6027893B2 (ja) | 2010-01-11 | 2016-11-16 | カッパーアールエヌエー，インコーポレイテッド | 性ホルモン結合グロブリン（ｓｈｂｇ）に対する天然アンチセンス転写物の阻害による性ホルモン結合グロブリン（ｓｈｂｇ）関連疾患の治療 |
| EP2529015B1 (en) | 2010-01-25 | 2017-11-15 | CuRNA, Inc. | Treatment of rnase h1 related diseases by inhibition of natural antisense transcript to rnase h1 |
| CN102844435B (zh) | 2010-02-22 | 2017-05-10 | 库尔纳公司 | 通过抑制吡咯啉‑5‑羧酸还原酶1(pycr1)的天然反义转录物而治疗pycr1相关疾病 |
| RU2612884C2 (ru) | 2010-04-02 | 2017-03-13 | Курна, Инк. | Лечение заболеваний, связанных с колониестимулирующим фактором 3 (csf3), путем ингибирования природного антисмыслового транскрипта k csf3 |
| WO2011127337A2 (en) | 2010-04-09 | 2011-10-13 | Opko Curna Llc | Treatment of fibroblast growth factor 21 (fgf21) related diseases by inhibition of natural antisense transcript to fgf21 |
| WO2011139387A1 (en) | 2010-05-03 | 2011-11-10 | Opko Curna, Llc | Treatment of sirtuin (sirt) related diseases by inhibition of natural antisense transcript to a sirtuin (sirt) |
| TWI531370B (zh) | 2010-05-14 | 2016-05-01 | 可娜公司 | 藉由抑制ｐａｒ４天然反股轉錄本治療ｐａｒ４相關疾病 |
| US8895528B2 (en) | 2010-05-26 | 2014-11-25 | Curna, Inc. | Treatment of atonal homolog 1 (ATOH1) related diseases by inhibition of natural antisense transcript to ATOH1 |
| ES2664585T3 (es) | 2010-05-26 | 2018-04-20 | Curna, Inc. | Tratamiento de enfermedades relacionadas con metionina sulfóxido reductasa (MSRA) mediante inhibición del transcrito antisentido natural a MSRA |
| EP2576785A4 (en) * | 2010-06-04 | 2014-12-24 | Univ Texas | METABOLIC CHANGE BY ME-378 |
| CN109112126B (zh) | 2010-06-23 | 2024-06-14 | 库尔纳公司 | 通过抑制电压门控钠通道α亚基(SCNA)的天然反义转录物而治疗SCNA相关疾病 |
| JP5998131B2 (ja) | 2010-07-14 | 2016-09-28 | カッパーアールエヌエー，インコーポレイテッド | Ｄｉｓｃｓｌａｒｇｅｈｏｍｏｌｏｇ（ｄｌｇ）ｄｌｇ１への天然アンチセンス転写物の阻害によるｄｌｇ関連疾患の治療 |
| CN103210086B (zh) | 2010-10-06 | 2017-06-09 | 库尔纳公司 | 通过抑制唾液酸酶4(neu4)的天然反义转录物而治疗neu4相关疾病 |
| KR101865433B1 (ko) | 2010-10-22 | 2018-07-13 | 큐알엔에이, 인크. | 알파-l 이두로니다아제 (idua)에 대한 자연 안티센스 전사체의 저해에 의한 idua 관련된 질환의 치료 |
| US10000752B2 (en) | 2010-11-18 | 2018-06-19 | Curna, Inc. | Antagonat compositions and methods of use |
| WO2012071238A2 (en) | 2010-11-23 | 2012-05-31 | Opko Curna Llc | Treatment of nanog related diseases by inhibition of natural antisense transcript to nanog |
| WO2012082765A2 (en) | 2010-12-16 | 2012-06-21 | The United State Of America. As Represented By The Secretary Department Of Health And Human Services | Methods for decreasing body weight and treating diabetes |
| EP2673361B1 (en) | 2011-02-08 | 2016-04-13 | Ionis Pharmaceuticals, Inc. | Oligomeric compounds comprising bicyclic nucleotides and uses thereof |
| KR102043422B1 (ko) | 2011-06-09 | 2019-11-11 | 큐알엔에이, 인크. | 프라탁신 (fxn)에 대한 자연 안티센스 전사체의 저해에 의한 프라탁신 (fxn) 관련된 질환의 치료 |
| MX365525B (es) | 2011-09-06 | 2019-06-06 | Curna Inc | Compuestos que regulan la expresión de subunidades alfa de canales de sodio regulados por voltaje en enfermedades relacionadas con epilepsia mioclónica severa de la infancia. |
| HK1210211A1 (en) | 2012-03-15 | 2016-04-15 | 科纳公司 | Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf |
| CN104837996A (zh) | 2012-11-15 | 2015-08-12 | 罗氏创新中心哥本哈根有限公司 | 抗apob反义缀合物化合物 |
| SG10201913068PA (en) | 2013-06-04 | 2020-02-27 | Harvard College | Rna-guided transcriptional regulation |
| JP7012033B2 (ja) | 2016-06-17 | 2022-02-10 | エフ．ホフマン－ラ ロシュ アーゲー | インビトロ腎毒性スクリーニングアッセイ |
| CN109328236B (zh) * | 2016-06-17 | 2022-10-25 | 豪夫迈·罗氏有限公司 | 体外肾毒性筛选测定法 |
| WO2018160772A1 (en) | 2017-02-28 | 2018-09-07 | The United State Of America, As Represented By The Secretary, Department Of Health & Human Services | Method of treating obesity, insulin resistance, non-alcoholic fatty liver disease including non-alcoholic steatohepatitis |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2601676B1 (fr) | 1986-07-17 | 1988-09-23 | Rhone Poulenc Sante | Procede de preparation du taxol et du desacetyl-10 taxol |
| US5108921A (en) | 1989-04-03 | 1992-04-28 | Purdue Research Foundation | Method for enhanced transmembrane transport of exogenous molecules |
| US5278324A (en) | 1990-08-28 | 1994-01-11 | Virginia Tech Intellectual Properties, Inc. | Water soluble derivatives of taxol |
| MX9102128A (es) | 1990-11-23 | 1992-07-08 | Rhone Poulenc Rorer Sa | Derivados de taxano,procedimiento para su preparacion y composicion farmaceutica que los contiene |
| US6030954A (en) * | 1991-09-05 | 2000-02-29 | University Of Connecticut | Targeted delivery of poly- or oligonucleotides to cells |
| US5227400A (en) | 1991-09-23 | 1993-07-13 | Florida State University | Furyl and thienyl substituted taxanes and pharmaceutical compositions containing them |
| US5250683A (en) | 1991-09-23 | 1993-10-05 | Florida State University | Certain substituted taxanes and pharmaceutical compositions containing them |
| US5272171A (en) | 1992-02-13 | 1993-12-21 | Bristol-Myers Squibb Company | Phosphonooxy and carbonate derivatives of taxol |
| FR2688518B1 (fr) | 1992-03-13 | 1994-05-06 | Rhone Poulenc Rorer Sa | Procede de preparation de derives du taxane. |
| US5248796A (en) | 1992-06-18 | 1993-09-28 | Bristol-Myers Squibb Company | Taxol derivatives |
| US5254580A (en) | 1993-01-19 | 1993-10-19 | Bristol-Myers Squibb Company | 7,8-cyclopropataxanes |
| US5672659A (en) | 1993-01-06 | 1997-09-30 | Kinerton Limited | Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides |
| US5801154A (en) * | 1993-10-18 | 1998-09-01 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of multidrug resistance-associated protein |
| US5595760A (en) | 1994-09-02 | 1997-01-21 | Delab | Sustained release of peptides from pharmaceutical compositions |
| US5882914A (en) | 1995-06-06 | 1999-03-16 | The Johns Hopkins University School Of Medicine | Nucleic acids encoding the hypoxia inducible factor-1 |
| US6770748B2 (en) * | 1997-03-07 | 2004-08-03 | Takeshi Imanishi | Bicyclonucleoside and oligonucleotide analogue |
| US5994076A (en) * | 1997-05-21 | 1999-11-30 | Clontech Laboratories, Inc. | Methods of assaying differential expression |
| JP4236812B2 (ja) | 1997-09-12 | 2009-03-11 | エクシコン エ／エス | オリゴヌクレオチド類似体 |
| US6238921B1 (en) * | 1998-03-26 | 2001-05-29 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of human mdm2 expression |
| EP1064378A2 (en) | 1998-03-27 | 2001-01-03 | The Board Of Trustees Of The Leland Stanford Junior University | Hypoxia-inducible human genes, proteins, and uses thereof |
| US6821724B1 (en) * | 1998-09-17 | 2004-11-23 | Affymetrix, Inc. | Methods of genetic analysis using nucleic acid arrays |
| KR20020013513A (ko) | 1999-03-18 | 2002-02-20 | 추후제출 | Ｘｙｌｏ-ｌｎａ 유사체 |
| DE60029314T2 (de) | 1999-03-24 | 2007-07-12 | Exiqon A/S | Verbesserte Synthese für -2.2.1. I Bicyclo-Nukleoside |
| WO2000064262A1 (en) | 1999-04-26 | 2000-11-02 | The University Of North Carolina At Chapel Hill | Antisense human fucosyltransferase sequences and methods of use thereof |
| US7053207B2 (en) | 1999-05-04 | 2006-05-30 | Exiqon A/S | L-ribo-LNA analogues |
| WO2000076497A1 (en) | 1999-06-14 | 2000-12-21 | Cancer Research Ventures Limited | Cancer therapy |
| EP1191941A4 (en) | 1999-06-21 | 2006-12-13 | Murdoch Childrens Res Inst | METHOD OF PROPHYLAXIS AND / OR TREATMENT OF CLINICAL DISORDERS |
| US6168950B1 (en) * | 1999-07-23 | 2001-01-02 | Isis Pharmaceuticals, Inc. | Antisense modulation of MEKK1 expression |
| AU7406700A (en) | 1999-10-04 | 2001-05-10 | Exiqon A/S | Design of high affinity rnase h recruiting oligonucleotide |
| US6706505B1 (en) * | 2000-03-08 | 2004-03-16 | Amgen Inc | Human E3α ubiquitin ligase family |
| AU2001295531A1 (en) * | 2000-09-02 | 2002-03-13 | Grünenthal GmbH | Antisense oligonucleotides against vanilloid receptor 1 |
| JP4413493B2 (ja) | 2000-10-04 | 2010-02-10 | サンタリス ファーマ アー／エス | プリンｌｎａ類似体の改善された合成方法 |
| WO2002034291A2 (en) | 2000-10-26 | 2002-05-02 | The Brigham And Women's Hospital, Inc. | Compositions and methods for treating hematologic malignancies and multiple drug resistance |
| AU2002317437A1 (en) | 2001-05-18 | 2002-12-03 | Cureon A/S | Therapeutic uses of lna-modified oligonucleotides in infectious diseases |
| US7700754B1 (en) | 2001-06-05 | 2010-04-20 | Masahiro Hiraoka | Polypeptide for unstabilizing protein in cells under aerobic conditions and DNA encoding the same |
| US7153954B2 (en) * | 2001-07-12 | 2006-12-26 | Santaris Pharma A/S | Method for preparation of LNA phosphoramidites |
| ATE287413T1 (de) | 2001-07-12 | 2005-02-15 | Santaris Pharma As | Verfahren zur herstellung des lna phosphoramidite |
| AU2003225495B2 (en) * | 2002-04-05 | 2009-01-15 | Roche Innovation Center Copenhagen A/S | Oligomeric compounds for the modulation HIF-1alpha expression |
| AU2003222743B2 (en) | 2002-05-08 | 2008-12-11 | Roche Innovation Center Copenhagen A/S | Synthesis of locked nucleic acid derivatives |
| NZ540779A (en) | 2002-11-01 | 2008-05-30 | Univ Pennsylvania | Compositions and methods for siRNA inhibition of HIF-1 alpha |
| WO2004046160A2 (en) | 2002-11-18 | 2004-06-03 | Santaris Pharma A/S | Amino-lna, thio-lna and alpha-l-oxy-ln |
| US7144999B2 (en) * | 2002-11-23 | 2006-12-05 | Isis Pharmaceuticals, Inc. | Modulation of hypoxia-inducible factor 1 alpha expression |
| JP2006518197A (ja) | 2003-02-10 | 2006-08-10 | サンタリス・ファルマ・アクティーゼルスカブ | ラス発現の改変のためのオリゴマー化合物 |
| DK1592793T3 (da) | 2003-02-10 | 2009-10-26 | Santaris Pharma As | Oligomeriske forbindelser for modulation af Survivin ekspression |
| MX2007005558A (es) * | 2004-11-09 | 2008-01-31 | Santaris Pharma As | Oligonucleotidos de lna potentes para la inhibicion dela expresion de hif-1a. |
-
2005
- 2005-11-09 MX MX2007005558A patent/MX2007005558A/es unknown
- 2005-11-09 DE DE602005022768T patent/DE602005022768D1/de not_active Expired - Lifetime
- 2005-11-09 NZ NZ555644A patent/NZ555644A/en not_active IP Right Cessation
- 2005-11-09 EA EA200701033A patent/EA014097B1/ru not_active IP Right Cessation
- 2005-11-09 AU AU2005304112A patent/AU2005304112B2/en not_active Ceased
- 2005-11-09 BR BRPI0515726A patent/BRPI0515726A8/pt not_active Application Discontinuation
- 2005-11-09 CA CA2587173A patent/CA2587173C/en not_active Expired - Fee Related
- 2005-11-09 EP EP05800760A patent/EP1833840B9/en not_active Expired - Lifetime
- 2005-11-09 WO PCT/DK2005/000721 patent/WO2006050734A2/en not_active Ceased
- 2005-11-09 US US11/271,686 patent/US7589190B2/en not_active Expired - Fee Related
- 2005-11-09 KR KR1020077012303A patent/KR101176245B1/ko not_active Expired - Fee Related
- 2005-11-09 DK DK05800760.0T patent/DK1833840T3/da active
- 2005-11-09 JP JP2007539463A patent/JP4825807B2/ja not_active Expired - Fee Related
- 2005-11-09 AT AT05800760T patent/ATE476441T1/de not_active IP Right Cessation
-
2007
- 2007-05-08 IL IL183054A patent/IL183054A0/en not_active IP Right Cessation
- 2007-06-08 NO NO20072933A patent/NO341878B1/no not_active IP Right Cessation
-
2009
- 2009-06-03 US US12/477,261 patent/US7939507B2/en not_active Expired - Fee Related
-
2011
- 2011-04-04 US US13/079,525 patent/US8410071B2/en not_active Expired - Fee Related
- 2011-08-15 JP JP2011177731A patent/JP2011229540A/ja not_active Withdrawn
-
2014
- 2014-02-21 JP JP2014031436A patent/JP2014098027A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008518608A5 (https=) | ||
| JP6899509B2 (ja) | 呼吸器疾患関連遺伝子特異的ｓｉＲＮＡ、そのようなｓｉＲＮＡを含む二重らせんオリゴＲＮＡ構造体およびこれを含む呼吸器疾患予防または治療用組成物 | |
| JP7007304B2 (ja) | Ｂ型肝炎感染症治療用のＰＡＰＤ５又はＰＡＰＤ７のｍＲＮＡ減少用核酸分子 | |
| KR102208588B1 (ko) | 신규 이중 나선 올리고 rna 및 이를 포함하는 섬유증 또는 호흡기 질환의 예방 또는 치료용 약학조성물 | |
| JP5981625B2 (ja) | Ｈｓｆ１関連疾患を処置するための有機組成物 | |
| JP2022515503A (ja) | 核酸、当該核酸を含む組成物及び複合体ならびに調製方法と使用 | |
| JP2016513976A5 (https=) | ||
| JP2022534069A (ja) | 核酸、薬物組成物及び複合体並びに調製方法と使用 | |
| WO2013105022A2 (en) | Organic compositions to treat beta-catenin-related diseases | |
| EP3509700A1 (en) | Pd-1 specific aptamers | |
| KR101715228B1 (ko) | 뎅기 바이러스 특이적 siRNA, 그러한 siRNA 를 포함하는 이중나선 올리고 RNA 구조체 및 이를 포함하는 뎅기 바이러스 증식 억제용 조성물 | |
| JP7464709B2 (ja) | Ｃｔｇｆ遺伝子特異的二重鎖オリゴヌクレオチド及びこれを含む線維症関連疾患及び呼吸器関連疾患の予防及び治療用組成物 | |
| US9233119B2 (en) | Use of HGMA-targeted phosphorothioate DNA aptamers to suppress carcinogenic activity and increase sensitivity to chemotherapy agents in human cancer cells | |
| EP3268011A2 (en) | Inhibitors of dek protein and related methods | |
| JP5730508B2 (ja) | 炎症性腸疾患の治療又は予防剤 | |
| JP5777240B2 (ja) | 新規オリゴヌクレオチド誘導体及びそれから成るＮＦ−κＢデコイ | |
| KR20260007508A (ko) | 진균 표적 안티센스 올리고뉴클레오타이드 및 이의 용도 | |
| TW202603167A (zh) | 用於抑制ｆｘｉ表現之聚核酸分子、醫藥組合物及其用途 | |
| AU2014280918B2 (en) | Organic compositions to treat HSF1-related diseases | |
| WO2016109522A1 (en) | Particle-nucleic acid conjugates and therapeutic uses related thereto | |
| CN121969748A (zh) | 一种新的siRNA、包含其的组合物及用途 | |
| HK40016323A (en) | Respiratory disease-related gene specific sirna, double-helical oligo rna structure containing sirna, compositon containing same for preventing or treating respiratory disease | |
| BR112016000163B1 (pt) | Estrutura de oligo rna de dupla hélice, nanopartículas, composição farmacêutica e formulação liofilizada | |
| AU2017201838A1 (en) | Organic compositions to treat Beta-ENac-related diseases | |
| NZ788062A (en) | Nucleic acid molecules for reduction of papd5 or papd7 mrna for treating hepatitis b infection |